Mission & Vision
We’re advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
Our Novel Platform
Introducing our novel platform for neurodegenerative disease
Our investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease.
Leveraging our platform across multiple neurodegenerative diseases.
Mild Cognitive Impairment
Latest News & Updates
Stay up to date
Mar 14, 2022
Ushering in a New Class of Disease-Modifying DTx
Mar 11, 2022
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients
Mar 7, 2022
Fierce Medtech's 2021 Fierce 15
Jan 27, 2022
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
Join our growing team
Clinical Trial Manager
Signal Processing Scientist/Engineer